Tamoxifen indications

List of indications
Metastatic breast cancer Adjuvant treatment of breast cancer Axillary node-negative breast cancer Contralateral breast cancer Ductal Carcinoma in Situ (DCIS) Reduction in breast cancer incidence in high risk women

Metastatic breast cancer
Tamoxifen citrate tablets are effective in the treatment of metastatic breast cancer in women and men. In premenopausal women with metastatic breast cancer, Tamoxifen is an alternative to oophorectomy or ovarian irradiation. Available evidence indicates that patients whose tumors are estrogen receptor positive are more likely to benefit from Tamoxifen therapy. Return to top

Adjuvant treatment of breast cancer
Tamoxifen citrate tablets are indicated for the treatment of node-positive breast cancer in postmenopausal women following total mastectomy or segmental mastectomy, axillary dissection, and breast irradiation. In some Tamoxifen adjuvant studies, most of the benefit to date has been in the subgroup with 4 or more positive axillary nodes. Return to top

Axillary node-negative breast cancer
Tamoxifen is indicated for the treatment of axillary node-negative breast cancer in women following total mastectomy or segmental mastectomy, axillary dissection, and breast irradiation. Return to top

Contralateral breast cancer
Tamoxifen reduces occurrence of contralateral breast cancer in patients receiving adjuvant Tamoxifen therapy for breast cancer. Return to top

Ductal Carcinoma in Situ (DCIS)
In women with DCIS, following breast surgery and radiation, Tamoxifen citrate tablets are indicated to reduce the risk of invasive breast cancer. The decision regarding therapy with Tamoxifen for the reduction in breast cancer incidence should be based upon an individual assessment of the benefits and risks of Tamoxifen therapy. Return to top

Reduction in breast cancer incidence in high risk women
Tamoxifen citrate tablets are indicated to reduce the incidence of breast cancer in women at high risk for breast cancer. This effect was shown in a study of 5 years planned duration with a median follow-up of 4.2 years. Twenty-five percent of the participants received drug for 5 years. The longer-term effects are not known. In this study, there was no impact of Tamoxifen on overall or breast cancer-related mortality .Tamoxifen citrate tablets are indicated only for high-risk women. "High risk" is defined as women at least 35 years of age with a 5-year predicted risk of breast cancer ≥ 1.67%, as calculated by the Gail Model. Return to top